Clinical Trials
14 trialsNCT05564377 2026-05-27
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05472792 2026-05-26
CAMERAN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT00585507 2026-05-22
Efficacy and Safety of 500mg of Fulvestrant
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT05392608 2026-05-22
SEQUEL-Breast
Borstkanker Onderzoek Groep
Phase 2 Active not recruiting
NCT07117630 2026-05-19
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
Fudan University
Phase 2 Recruiting
NCT07340619 2026-05-19
EPIBREAST
UNICANCER
Phase 2 Not yet recruiting
NCT06428396 2026-05-18
LITESPARK-029
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07405801 2026-05-18
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT05085002 2026-05-14
A Study of Lerociclib in Participants With Advanced Breast Cancer
EQRx International, Inc.
Phase 2 Terminated
NCT06979596 2026-05-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07368998 2026-05-11
optINAVO
Hoffmann-La Roche
Phase 2 Recruiting
NCT05601440 2026-05-07
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT04553133 2026-05-06
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Phase 2 Active not recruiting
NCT03179904 2026-05-05
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting